1. |
赵岚, 杨烽华, 张少衡. 肿瘤心脏病学及抗肿瘤药物的心脏毒性. 生理科学进展, 2017, 48(3): 197-202.
|
2. |
Francis SA, Asnani A, Neilan T, et al. Optimizing cardio-oncology programs for cancer patients. Future Oncol, 2015, 11(14): 2011-2015.
|
3. |
Bellinger AM, Arteaga CL, Force T, et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation, 2015, 132(23): 2248-2258.
|
4. |
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol, 2014, 64(9): 938-945.
|
5. |
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J, 2016, 37(36): 2768-2801.
|
6. |
隋道敬, 冯晓敬, 徐慧. 保心康预防阿霉素为主化疗方案导致心脏毒性 60 例临床研究. 中医杂志, 2004, 45(4): 272-273.
|
7. |
代国华, 陈明媚. 稳心颗粒干预蒽环类抗肿瘤药物引起心律失常的临床观察. 亚太传统医药, 2011, 7(3): 59-60.
|
8. |
周爱民. 稳心颗粒治疗蒽环类抗肿瘤药物诱发的心律失常的临床疗效观察. 肿瘤药学, 2011, 1(6): 535-537.
|
9. |
刘红梅, 刘世专, 黄卫俊, 等. 稳心颗粒在乳腺癌蒽环类化疗引起心脏毒性患者中的应用及预后. 中国现代药物应用, 2017, 11(8): 123-124.
|
10. |
Patanè S. Cardiotoxicity: anthracyclines and long term cancer survivors. Int J Cardiol, 2014, 176(3): 1326-1328.
|
11. |
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention rehabilitation (EACPR). Eur Heart J, 2016, 37(29): 2315-2381.
|
12. |
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 2002, 20(5): 1215-1221.
|
13. |
郑梦颖, 陈晓品. 化疗药物对重要脏器不良反应的研究进展. 重庆医学, 2012, (14): 1431-1433.
|
14. |
中国临床肿瘤学会中华医学会血液学分会. 蒽环类药物心脏毒性防治指南 (2013 年版). 临床肿瘤学杂志, 2013, 18(10): 925-934.
|
15. |
蔡亚红, 唐方明. 蒽环类药物的心脏毒性预防措施研究进展. 新乡医学院学报, 2018, (3): 244-247.
|
16. |
Stěrba M, Popelová O, Vávrová A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal, 2013, 18(8): 899-929.
|
17. |
Fulbright JM, Egas-Bejar DE, Huh WW, et al. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy. Cancer Chemother Pharmacol, 2015, 76(6): 1297-1307.
|
18. |
Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother, 2007, 8(8): 1039-1058.
|
19. |
沈映君. 中药药理学. 上海: 上海科学技术出版社, 2007: 162-163.
|
20. |
杨从信, 余群. 甘松整律汤治疗室性早搏 35 例疗效观察. 云南中医学院学报, 2000, 23(1): 32-33.
|
21. |
陈鹏. 步长稳心颗粒治疗冠心病合并心律失常临床观察. 生物磁学, 2005, 5(2): 21-22.
|
22. |
中国生物医学工程学会心脏起搏与电生理分会, 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, 等. 胺碘酮抗心律失常治疗应用指南. 中华心血管病杂志, 2006, 32(12): 1065-1071.
|
23. |
王浴生, 邓文龙, 薛春生, 主编. 中药药理与应用 (第 2 版). 北京: 人民卫生出版社, 1994: 38, 192-193, 429, 986.
|